Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | M6PR | P20645 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 2/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
| ▸ | IDUA | P35475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19774832 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL25788571 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL18271877 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL26715975 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL16392508 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL26715981 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL17636458 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL18269757 | 1.00 | SUCNR1 (0.36) | SUCNR1CA9CA12CA2M6PR | |
| SCHEMBL19488918 | 0.89 | F10 (0.39) | M6PR | |
| SCHEMBL18969723 | 0.89 | F10 (0.39) | M6PR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019513-B1 | SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 1 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2018-01-17 | — | — | EP | disclosed |
| US-20120289611-A1 | PECTIN COMPOUNDS, METHODS OF USING PECTIN COMPOUNDS, AND METHODS OF CONTROLLING WATER SOLUBILITY | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA FOR AND ON BEHALF OF ITS COMPONENT INSTITUTION, THE UNIVERSITY OF ALABAMA | 2012-11-15 | — | — | US | disclosed |
| US-8241837-B2 | Mask pattern for semiconductor device fabrication, method of forming the same, and method of fabricating finely patterned semiconductor device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-08-14 | — | — | US | disclosed |
| WO-2011041384-A2 | PECTIN COMPOUNDS, METHODS OF USING PECTIN COMPOUNDS, AND METHODS OF CONTROLLING WATER SOLUBILITY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110059613-A1 | MASK PATTERN FOR SEMICONDUCTOR DEVICE FABRICATION, METHOD OF FORMING THE SAME, AND METHOD OF FABRICATING FINELY PATTERNED SEMICONDUCTOR DEVICE | HAH JUNG-HWAN | 2011-03-10 | — | — | US | disclosed |
| US-7851125-B2 | Mask pattern for semiconductor device fabrication, method of forming the same, and method of fabricating finely patterned semiconductor device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-12-14 | — | — | US | disclosed |
| US-7790700-B2 | Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-07 | — | — | US | disclosed |
| US-20080051567-A1 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | SIGMA-TAU INDUSTRIE FARMACEUTICHERIUNITE S.P.A. (IT) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051567-A1 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | HPSE, SERPINC1, PLAUR | SUCNR1 561/4885CA9 514/4885CA12 582/4885 |
| US-20120289611-A1 | PECTIN COMPOUNDS, METHODS OF USING PECTIN COMPOUNDS, AND METHODS OF CONTROLLING WATER SOLUBILITY | DDOST, PHYKPL, PWWP2B | SUCNR1 4053/4885CA9 550/4885CA12 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.